Benzinga | Aug 12, 2021 06:32AM EDT

HC Wainwright & Co. Maintains Buy on ADMA Biologics, Lowers Price Target to $6

HC Wainwright & Co. analyst Raghuram Selvaraju maintains ADMA Biologics (NASDAQ:ADMA) with a Buy and lowers the price target from $7 to $6.